Navigation Links
PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
Date:11/5/2013

"expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views only as of the date of this release. We anticipate that subsequent events and developments will cause the our views to change. However, while PTC may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
2. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
3. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
4. Mast Therapeutics Reports Third Quarter 2013 Financial Results
5. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
6. Echo Therapeutics Schedules Third Quarter 2013 Financial Results for Thursday, November 7, 2013
7. G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum
8. Cell Therapeutics Reports Third Quarter 2013 Financial Results
9. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
10. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
11. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Baptist Health Lexington is the first facility in ... with Electrophysiology Services (EPS) Accreditation status from the Society of ... most common cardiac arrhythmia and has become recognized as a ... and possible death. More than 5 million patients in ... the numbers are rapidly increasing as the population ages. ...
(Date:12/19/2014)... CITY, Kan. , Dec. 18, 2014 /PRNewswire/ ... PETX ), a biopharmaceutical company focused on the ... companion animals, today announced positive results from its ... innovative drug for treating pain in dogs with ... improvements in pain assessment scores that were statistically ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
Breaking Medicine Technology:Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... 30 Sirion Therapeutics, Inc. announced today ... products, pipeline and research will be presented ... Association for Research in Vision and Ophthalmology ... http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )These presentations include ...
... Two Phase 3 studies to start in the second ... Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: ... are extending their global development program for VEGF Trap-Eye, ... diseases, to include Central Retinal Vein Occlusion (CRVO). The ...
Cached Medicine Technology:Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 2Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 4Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 5
(Date:12/22/2014)... 2014 Coral Gables is preparing to welcome ... Troopers, with its new clinic location set to open in ... hassle out of dealing with this common childhood parasite by ... two salon clinic locations in South Florida, or in the ... decision to expand developed naturally out of the demand for ...
(Date:12/22/2014)... New York (PRWEB) December 22, 2014 The ... a staple of the season. Many may be thinking about ... a span of a few weeks. Health Republic Insurance of ... of Registered Dietitian, Andrea Chernus, to provide some smart ideas ... and stay healthy. , 1)    Avoid arriving at a holiday gathering ...
(Date:12/22/2014)... Shanghai, China (PRWEB) December 22, 2014 ... for MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma ... Health , a leading global healthcare consulting firm. MabThera ... B-cell lymphoma (DLBCL), the most common form of NHL. ... Market Access and Barriers,” the incidence of NHL in ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Only weeks ... southern and mid-western cities to have a battery manufacturer ... TalkLocal ( http://www.talklocal.com ) is launching in Henderson ... economy. , “A strong manufacturing sector is going ... founder Gurpreet Singh explained, “and TalkLocal works with small ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... latest issue of Deutsches rzteblatt International ( ... research group presents epidemiological data. The authors surveyed ... specializing in the treatment of HIV patients in the ... to analyze the largest collection of data on the ...
... care information systems is a multibillion dollar industry. The ... to talk to each other regularly attract media comment. However ... Open Source, that could address many of these problems, because ... systems. Now new research by the University of Warwick,s ...
... Metabolomics is a post-genomic research field for analysis of ... approaches offer an analysis of metabolite level changes in ... in identifying the new diagnostic markers and therapeutic targets ... scarce. A research article to be published on ...
... an inflammatory obliterative cholangiopathy with unknown etiology, leading ... as an indispensable research tool for gene expression ... underlying BA, and allows the simultaneous analysis of ... studies have been performed to investigate the gene ...
... The best prescription for patients with venous leg ulcers is ... A five-year study led from the University of Leeds ... the healing process of leg ulceration contrary to what ... cheaper and easier to deliver, work just as well, the ...
... Reporter , MONDAY, March 7 (HealthDay News) -- Interactive ... kids, metabolisms to levels typically seen with moderate or ... the effect of six forms of so-called "exergaming" on ... (BMIs) at a youth fitness research and training center ...
Cached Medicine News:Health News:Resaerch finds open-source software is actually more secure for health care IT 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Video Games That Make Kids Move Burn Calories 2
Inquire...
Inquire...
... X-22 Series is up to 10 inches/ 25 cm ... 11 rotors, the Allegra X-22 Series is the space-saving ... Only 18 inches / 46 cm wide • 11 ... 3 different ways to Spin 1.5 mL & ...
... Optimal for Subcellular Fractionation, Proteins ... g (30,000 rpm) with fixed-angle ... 0.25 up to 85 mL ... C to 40° C • ...
Medicine Products: